Benign Prostatic Hyperplasia (Enlarged Prostate) Clinical Trials

Now enrolling for a research study for enlarged prostate. For more information contact: Clinical Trials of Texas, Inc. 210-949-0122.

If you have benign prostatic hyperplasia (BPH) and overactive bladder (OAB), you may qualify for a research study at Advanced Clinical Research (ACR). It’s not uncommon for men diagnosed with benign prostatic hyperplasia (BPH) to also be suffering from overactive bladder symptoms (OAB). Therefore, medications for both conditions may need ...

A Randomized, Double-blind, Placebo-controlled Dose-ranging Study of OPK-88004 Once-a-day Dosing for 16 Weeks in Men with Signs and Symptoms of Benign Prostatic Hyperplasia

This study will evaluate the safety and effectiveness of different doses of OPK-88004 compared to placebo on prostate size and related lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH).

This clinical trial is designed as a randomized, placebo-controlled, multi-center phase 2 trial to evaluate the efficacy and safety of OPK-88004 in men with benign prostatic hyperplasia. Eligible subjects will be randomized into one of two OPK-88004 treatment groups or a placebo group after a 4-week screening period. Subjects will ...

Overview The aim of this study is to compare two different surgical methods for treating benign prostatic obstruction (BPO). The investigators are going to compare the risks and benefits of bipolar transurethral resection of the prostate (TURP) and bipolar transurethral enucleation of the prostate (BipolEP). Furthermore, the investigators are going ...

The known correlation between benign prostatic hypertrophy (BPH) and hypertension could be explained by 3 theoretical pathway models. Whether hypertension causes BPH, BPH causes hypertension or the two are caused by a common factor is currently unknown. In this study it will be investigated whether hypertension is due to the ...

T-ACE Beads can be used for prostatic arterial embolization safely and efficiently. Furthermore, investigator's microspheres has advantageous characteristics in biodegradability, drug delivery capability, and cost-effectiveness. After the clinical trial, we anticipate introducing a new microsphere for Lower Urinary Tract Symptom/Benign prostatic hyperplasia patients, which is beneficial to the participants in ...

Every year in France, more than 60 000 people are operated for benign prostatic hyperplasia (BPH). This surgery is accompanied by a change or even a loss of ejaculations externalized what constitutes the main constraint for patients. Empirically, the investigators talk to the patient "retrograde ejaculation" to explain a possible ...

Primary Study Objective: The study's primary objective is to assess the efficacy of the MediTate iTind in subjects with symptomatic BPH by reduction of IPSS ) (International Prostate Symptoms Score) score. Secondary Study Objectives: To further evaluate the efficacy of MediTate iTind as determined by increase of maximal urinary peak ...